trending Market Intelligence /marketintelligence/en/news-insights/trending/OXUQT5w4jngKsiDm43OqYQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Ono Pharmaceutical secures license for 2 cancer compounds

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Ono Pharmaceutical secures license for 2 cancer compounds

Ono Pharmaceutical Co. Ltd. secured an exclusive license to develop and commercialize certain Karyopharm Therapeutics Inc. compounds for cancer in Japan, South Korea, Taiwan, Hong Kong and the Association of Southeast Asian Nations.

Ono will make a one-time upfront payment of ¥2.5 billion for the license to Selinexor and KPT-8602 which are currently under clinical development.

The company is also required to pay up to an additional ¥19.15 billion if certain development and commercial milestones are achieved as well as royalties once the drugs hit the market.

Karyopharm retains the rights to develop and commercialize the products outside the Ono territory.

As of Oct. 11, US$1 was equivalent to ¥112.28.